Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Here’s what to know. In February, Merck officials presented to Delaware’s Council of Development Finance to make their case for receiving a grant to invest in their ambitious project. During the ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

Merck Animal Health is investing $895 million in a new De Soto facility, which will bring hundreds of jobs to the area. The ...

Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington ...

Merck is constructing a $1 billion drug manufacturing facility in Wilmington, Delaware, as part of its commitment to investment and growth in the United States. The company on Tuesday said it ...

April 29 (Reuters) - U.S. drugmaker Merck (MRK.N), opens new tab said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with ...

Here’s what to know. In February, Merck officials presented to Delaware’s Council of Development Finance to make their case for receiving a grant to invest in their ambitious project.